|
Baricitinib (formerly INCB28050, LY3009104) is an oral JAK1 and JAK2 inhibitor. Baricitinib is in Phase III development by Eli Lilly and Incyte as a potential treatment for rheumatoid arthritis. It is in Phase II development as a potential treatment for psoriasis and diabetic nephropathy. The related compound in JAK inhibitor is Tofacitinib, currently approved for the treatment of rheumatoid arthritis (RA) in the United States. ==References== 抄文引用元・出典: フリー百科事典『 ウィキペディア(Wikipedia)』 ■ウィキペディアで「Baricitinib」の詳細全文を読む スポンサード リンク
|